UGENTi001-A-1

UGENT-MFS003-CRISPR

General

Cell Line

hPSCreg Name
UGENTi001-A-1
Alternative name(s)
UGENT-MFS003-CRISPR
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 30th January 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Ghent University (UGENT)
Owner Ghent University (UGENT)
Distributors
Derivation country Belgium

External Databases

BioSamples SAMEA112285422

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Marfan Syndrome
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Marfan Syndrome
  • Marfan's Syndrome
  • Marfan syndrome
Genetic variants
15q21.1
c.7754T>C
p.Ile2585Thr
Heterozygous

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA111501120

Ethics

Also have a look at the ethics information for the parental line UGENTi001-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Thermo Fisher (Sendai)
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line UGENTi001-A.
Passage number reprogrammed 3

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Morphology and growth characteristics
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
TrypLE
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Essential 8™
Supplements
Penicillin/Streptomycin 1 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
NANOG
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
FOXA2
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
HAND1
Yes
brachyury
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
SOX1
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46-XY (normal)
Passage number: 15
Karyotyping method: CNV-seq

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Marfan Syndrome
Synonyms
  • Marfan Syndrome
  • Marfan's Syndrome
  • Marfan syndrome
Genetic modifications
FBN1 (target)
Isogenic modification
15q21.1
c.7754T>C
p.Ile2585Thr
Heterozygous
Repaired